Franck de Laval1, Hubert d'Aubigny2, Séverine Mathéus3, Thomas Labrousse4, Anne Laure Ensargueix4, Enguerrane Martinez Lorenzi4, François Xavier Le Flem4, Nathalie André4, Didier Belleoud4, Isabelle Leparc-Goffart5, Dominique Rousset3, Fabrice Simon6, Sébastien Briolant7. 1. French Armed Forces Health Service in French Guiana, Cayenne, French Guiana; SSA, Service de Santé des Armées, CESPA, Centre d'épidémiologie et de santé publique des armées, Marseille, France; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France. Electronic address: franck.de-laval@intradef.gouv.fr. 2. Saint Anne Military Teaching Hospital, Toulon, France. 3. National Reference Center for Arboviruses, Institut Pasteur de la Guyane, Cayenne, French Guiana. 4. French Armed Forces Health Service in French Guiana, Cayenne, French Guiana. 5. National Reference Center for Arboviruses, Institut de Recherche Biomédicale des Armées, Marseille, France; Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France. 6. Laveran Military Teaching Hospital, Marseille, France. 7. French Armed Forces Health Service in French Guiana, Cayenne, French Guiana; Unité de Parasitologie et Entomologie, Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France; Aix Marseille Université, IRD, AP-HM, SSA, UMR Vecteurs - Infections Tropicales et Méditerranéennes (VITROME), IHU - Méditerranée Infection, Marseille, France.
Abstract
BACKGROUND: Although the complications of Zika virus infection have been well described, the clinical pattern has not been reported in enough detail to differentiate this infection from those with other arboviroses, and no longitudinal study has yet been published on the persistence of symptoms and quality of life. OBJECTIVES: were to describe bio-clinical pattern and quality of life during ZIKV infection, and their evolution. STUDY DESIGN: We present a 1-year clinical follow-up of 49 people infected with Zika virus in French Guiana, for whom the diagnosis was confirmed by RT-PCR in serum or urine. RESULTS: Fever was inconsistent (95% confidence interval (CI), 39-67). Exanthema (CI, 84-100) was maculopapular, with pruritus and conjunctivitis, variable over time and disappeared 12 days after the onset of symptoms (CI, 10-14). Joint pain (CI, 39-67) occurred mainly in the hands, wrists, knees and ankles and lasted for 10 days (CI, 7-13). Asthenia (CI, 61-85) scored low (3/10) but lasted for 19 days (CI, 16-22). The last two symptoms strongly limited patients' activities in the acute stage of the disease (RAPID-3 score, CI, 5-8). None of the patients had neurological complications, but 41% (CI, 27-55) had areflexia during the first month. CONCLUSIONS: We found no real chronic evolution or decreased quality of life, function or ability to work from the first month after symptom onset.
BACKGROUND: Although the complications of Zika virus infection have been well described, the clinical pattern has not been reported in enough detail to differentiate this infection from those with other arboviroses, and no longitudinal study has yet been published on the persistence of symptoms and quality of life. OBJECTIVES: were to describe bio-clinical pattern and quality of life during ZIKV infection, and their evolution. STUDY DESIGN: We present a 1-year clinical follow-up of 49 people infected with Zika virus in French Guiana, for whom the diagnosis was confirmed by RT-PCR in serum or urine. RESULTS: Fever was inconsistent (95% confidence interval (CI), 39-67). Exanthema (CI, 84-100) was maculopapular, with pruritus and conjunctivitis, variable over time and disappeared 12 days after the onset of symptoms (CI, 10-14). Joint pain (CI, 39-67) occurred mainly in the hands, wrists, knees and ankles and lasted for 10 days (CI, 7-13). Asthenia (CI, 61-85) scored low (3/10) but lasted for 19 days (CI, 16-22). The last two symptoms strongly limited patients' activities in the acute stage of the disease (RAPID-3 score, CI, 5-8). None of the patients had neurological complications, but 41% (CI, 27-55) had areflexia during the first month. CONCLUSIONS: We found no real chronic evolution or decreased quality of life, function or ability to work from the first month after symptom onset.
Authors: Pablo F Belaunzarán-Zamudio; Allyson Mateja; Paola Del Carmen Guerra-de-Blas; Héctor A Rincón-León; Karla Navarro-Fuentes; Emilia Ruiz-Hernández; Sandra Caballero-Sosa; Francisco Camas-Durán; Zoila Priego-Smith; José G Nájera-Cancino; Alexander López-Roblero; Karina Del Carmen Trujillo-Murillo; John H Powers; Sally Hunsberger; Sophia Siddiqui; John H Beigel; Raydel Valdés-Salgado; Guillermo Ruiz-Palacios Journal: PLoS Negl Trop Dis Date: 2021-02-16
Authors: Felipe Henriques Carvalho Soares; Gabriel Taricani Kubota; Ana Mércia Fernandes; Bruno Hojo; Catarina Couras; Bárbara Venturoti Costa; Jorge Dornellys da Silva Lapa; Luíza Mansur Braga; Matheus Merula de Almeida; Pedro Henrique Martins da Cunha; Vítor Hugo Honorato Pereira; Adriano Donizeth Silva de Morais; Manoel Jacobsen Teixeira; Daniel Ciampi de Andrade Journal: Eur J Pain Date: 2021-04-08 Impact factor: 3.651